PDCD1 and neoplasm: Remarkably, METTL3 plus anti-PD-1 therapy demonstrated synergistic inhibition of tumor growth as compared to control (p = 0.008), sgMETTL3 (p = 0.032), and anti-PD-1 (p = 0.008) groups (Figures 7B and 7C), achieving >90% reduction in tumor volume and weight.